A look into the Omnipod® 5 Automated Insulin Delivery System

Описание: Training is essential and must be completed before using the Omnipod 5 Automated Insulin Delivery System. As part of this process, you will need to meet with your healthcare provider and visit omnipod.com/setup to complete setup and schedule your required training.

Omnipod 5 Resources: https://www.omnipod.com/current-podde...

Omnipod 5 Pro Tip Series: https://www.omnipod.com/protips

*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

**Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM-12AM) with high blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Average overnight time (12AM-6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 3.6% vs. 1.2%; 2.5% vs. 1.2%. Average day time (6AM-12AM) with low blood glucose in adults/adolescents and children for standard therapy vs Omnipod 5 = 2.6% vs. 1.4%; 2.1% vs. 2.0%.

***Sherr J, et al. Diabetes Care (2022). Study in 80 children with T1D aged 2 to 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in children for standard therapy vs Omnipod 5 = 38.4% vs. 16.9%. Average day time (6AM-12AM) with high blood glucose in children for standard therapy vs Omnipod 5 = 39.7% vs. 33.7%. Average overnight time (12AM-6AM) with low blood glucose in children for standard therapy vs Omnipod 5 = 3.4% vs. 2.1%. Average day time (6AM-12AM) with low blood glucose in children for standard therapy vs Omnipod 5 = 3.4% vs. 2.6%.

****Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean overnight time greater than 180 mg/dL (12AM-6AM) as measured by CGM: ST = 50%, 3-mo Omnipod 5 = 30%. Mean daytime greater than 180 mg/dL (6AM-12AM) as measured by CGM: ST = 55%, 3-mo Omnipod 5 = 36%. Mean overnight time in less than 70 mg/dL (12AM-6AM) as measured by CGM: ST = 0.10%, 3-mo Omnipod 5 = 0.22%. Mean daytime less than 70 mg/dL (6AM-12AM) as measured by CGM: ST = 0.16%, 3-mo Omnipod 5 = 0.17%. Statistical testing not done to assess significance of change between ST phase and Omnipod 5 System phase.

The Omnipod 5 Automated Insulin Delivery (AID) System is cleared for individuals with type 1 diabetes ages 2 years and older and type 2 diabetes ages 18 and older.

The Omnipod 5 System is intended for single patient, home use and requires a valid prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.

WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.

For complete safety information including indications, contraindications, warnings, cautions, and instructions visit omnipod.com/safety. Consult your healthcare provider before starting on Omnipod 5.

#Omnipod #Omnipod5 #Diabetes #insulinpump